To Order: patrick@cotinis.com
IL-31 Polyclonal Antibody |
|||
| ES8589-50ul | ELK Biotech | 50ul | EUR 248.4 |
|
Description: A Rabbit Polyclonal antibody against IL-31 from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
|||
Polyclonal IL-31 Antibody |
|||
| APR06391G | Leading Biology | 0.1 mg | EUR 790.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human IL-31 . This antibody is tested and proven to work in the following applications: |
|||
Polyclonal IL-31 Antibody |
|||
| APR06392G | Leading Biology | 0.1 mg | EUR 790.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human IL-31 . This antibody is tested and proven to work in the following applications: |
|||
XMIR-31 RNA oligo miRNA-31-5p with Xmotif |
|||
| XMIR-31 | SBI | 10 rxn | EUR 525.6 |
AXMIR-31 RNA oligo anti-miRNA-31-5p with Xmotif |
|||
| AXMIR-31 | SBI | 10 reactions | EUR 525.6 |
IL-31 Antibody |
|||
| 3745-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: IL-31 Antibody: Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development. |
|||
IL-31 Antibody |
|||
| 3745-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: IL-31 Antibody: Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development. |
|||
IL-31 Antibody |
|||
| 3747-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: IL-31 Antibody: Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development. |
|||
IL-31 Antibody |
|||
| 3747-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: IL-31 Antibody: Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development. |
|||
IL-31 Antibody |
|||
| 24390-100ul | SAB | 100ul | EUR 468 |
IL-31 Antibody |
|||
| 24391-100ul | SAB | 100ul | EUR 468 |
Rabbit IL-31 ELISA Kit |
|||
| ERTI0041 | Abclonal | 96Tests | EUR 625.2 |
IL-31 |
|||
| E21-053 | EnoGene | 10ug | EUR 411.6 |
XMIRXpress lentivector miRNA-31-5p with Xmotif |
|||
| XMIRXP-31 | SBI | 10 ug | EUR 812.4 |
Canine Interleukin 31(IL-31) |
|||
| QY-E70194 | Qayee Biotechnology | 96T | EUR 511.2 |
IL-31, Interleukin-31, human |
|||
| RC212-42 | Bio Basic | 2ug | EUR 125.26 |
Anti-IL-31 Antibody |
|||
| A08339-1 | BosterBio | 100ug/vial | EUR 400.8 |
Anti-IL-31 antibody |
|||
| STJ98951 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to IL-31. |
|||
IL-31 Peptide |
|||
| 3745P | ProSci | 0.05 mg | EUR 197.7 |
|
Description: (NT) IL-31 peptide |
|||
IL-31 Peptide |
|||
| 3747P | ProSci | 0.05 mg | EUR 197.7 |
|
Description: (IN) IL-31 peptide |
|||
IL-31, Human |
|||
| HY-P7217 | MedChemExpress | 50ug | EUR 914.4 |
Recombinant Human Interleukin-31/IL-31 |
|||
| C053-10ug | Novoprotein | 10ug | EUR 242.4 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Human Interleukin-31/IL-31 |
|||
| C053-1mg | Novoprotein | 1mg | EUR 3774 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||